Context: Epidural steroid injections (ESIs) are a common, effective treatment of lumbar radiculopathy and sciatica. Although the negative skeletal effects of oral glucocorticoids are well established, little is known about the impact of ESI on bone quality.
pidural steroid injections (ESIs) are a commonly used and effective treatment of lumbar radiculopathy and sciatica (1) . Although the overall incidence of adverse effects of ESIs is low (2) , the skeletal complications of this therapy are poorly understood. Osteoporosis is a major complication of glucocorticoid treatment (3, 4) . Systemic glucocorticoids exert negative skeletal effects by inhibiting osteoblast differentiation and inducing osteoblast apoptosis, resulting in suppression of bone formation (5) . In addition, glucocorticoids accelerate bone loss by promoting the receptor activator of nuclear factor k-B ligand system and increasing osteoclast-mediated bone resorption (6) . Reduced osteocyte viability, along with increased urinary calcium absorption, also contributes to glucocorticoid-induced osteoporosis (3, 5, 7) . The drastic skeletal consequences of chronic oral glucocorticoid treatment are well established, and there is high-quality evidence from several studies supporting pharmacologic treatment of prevention and treatment of osteoporosis in these patients (8) (9) (10) (11) (12) (13) (14) (15) . In contrast, far less is known about the skeletal impact of ESIs. As a result, although there are clear guidelines for prevention and treatment of osteoporosis in patients using oral glucocorticoids (15) , there are currently no recommendations regarding patients receiving ESIs. Although systemic exposure with epidural steroids is far lower than with oral, some absorption does occur (16) . Previous studies of patients receiving ESI have demonstrated suppression of the hypothalamic-pituitaryadrenal axis (17, 18) as well as marked elevations in blood glucose in patients with diabetes (19) . Despite a potential deleterious skeletal effect, few studies have investigated the effects of ESIs on bone.
Dual-energy X-ray absorptiometry (DXA), the most commonly used clinical tool to evaluate bone mineral density (BMD), may have particular limitations in the population of patients receiving ESIs. DXA, which provides a two-dimensional measurement of bone density, is subject to artifact, particularly at the spine from degenerative joint diseases, spondylolisthesis, and arterial calcification (20) . As patients presenting for ESIs often have pathological changes at the spine, the utility of DXA to assess bone disease may be particularly limited in this population. DXA may also not be the optimal tool for assessment of potential effects of ESIs on bone, as studies have demonstrated that glucocorticoids negatively affect bone quality, predisposing patients to fracture, independent of their effects on areal BMD (aBMD) (21, 22) . Other imaging techniques may be needed for skeletal assessment in this population. Central quantitative CT (cQCT) provides a three-dimensional method for measuring volumetric BMD (vBMD) at the spine and hip, which is less susceptible to artifact from degenerative change or bone size (23) . For patients undergoing CT for clinical reasons, a potential opportunity exists for concurrent BMD screening of the lumbar spine (LS) without the need for any additional imaging, radiation exposure, or patient time (24) . Studies using cQCT have demonstrated clear deficits in vBMD (25) and stiffness (26) in patients treated with oral glucocorticoids. To date, there have been no studies using this technology to investigate the skeletal effects of ESIs.
This study used CT in patients with low back pain to elucidate the effects of ESIs on bone quality, assessed by vBMD of the LS. We hypothesized that patients treated with ESIs have lower vBMD compared with age-and sexmatched controls. We further hypothesized that there would be a dose response effect among patients treated with ESI, with higher cumulative ESI dose associated with lower vBMD.
Materials and Methods

Patients
This retrospective study included patients who had lumbar CT scans without contrast at the Hospital for Special Surgery between January 2011 and December 2016. Only adult patients were included. Cases were defined as patients who had documented ESIs (at least three injections) in the 5 years prior to the date of CT scan. Each case was matched to a control of the same sex and age (61 year) who also had a LS CT scan without contrast during the study period. The most common indications for CT scans were radiculopathy, spinal stenosis, and chronic low back pain. Exclusion criteria were as follows: history of hyperparathyroidism, osteomalacia, Cushing syndrome or other endocrinopathy, and previous LS surgery with hardware. Subjects were also excluded if they had documented use of oral or intravenous glucocorticoids for more than 2 weeks per year or had used teriparatide during the 5-year study period. The study was approved by the Institutional Review Board of the Hospital for Special Surgery.
Phantomless cQCT measurement
cQCT was performed using a phantomless software package (MindWays QCT Pro, Austin, TX). LS regions of interest were used to derive density measures. vBMD was measured at each level from T12 through L5. The regions of interest were determined automatically, manually reviewed by a radiologist, and repositioned if necessary. Vertebrae with compression fractures or strongly heterogeneous trabecular bone were excluded. Previous studies have found that vBMD tended to be higher when performed in the setting of contrast (27, 28) . Therefore, to rule out a potential confounding effect of IV contrast, we only included patients who had LS CT scans without contrast.
Statistical analyses
Statistical analysis was performed with SPSS (version 22.0; SPSS Inc., Chicago, IL). Normality testing (Shapiro Wilk) was performed, and variables that were not normally distributed were analyzed by nonparametric tests. Two-sided P values ,0.05 were considered to indicate statistical significance. Differences between ESI and control subjects were assessed by Student t test, Wilcoxon rank sum, or x 2 as indicated. All ESI doses were converted to triamcinolone equivalents for comparison (29) . Cumulative dose was calculated as the product of number of injections and dose in triamcinolone equivalents. The relationship between cumulative ESI dose and vBMD was assessed by Pearson correlation. Linear mixed models were used to investigate whether the magnitude of the difference in vBMD between ESI and control subjects was greater at the injection levels compared with more distal vertebrae.
Results
Study patients
Our study included 121 patients who had received three or more ESIs in the 5 years prior to their CT scans and 121 age-and sex-matched controls who had no documented ESI exposure. The demographic data for study subjects is summarized in Table 1 . The mean age of the subjects was 65 6 14 years. The majority were white, and half were women. Cases and controls were of similar height and weight. Tobacco use was similar between the two groups. Use of bisphosphonates, hormone replacement therapy, and raloxifene was similar between the groups as well. The most common diagnoses necessitating ESIs were spinal stenosis (63%) and radiculopathy (23%).
ESI dose
Among patients treated with ESI, the number of injections ranged from 3 to 16, with a median of 4. The most commonly used glucocorticoid preparation was triamcinolone, followed by betamethasone and dexamethasone. The median cumulative dosage of ESI was 340 mg of triamcinolone equivalent, with a range from 150 to 1400 mg. The majority of patients (97 subjects, 80%) received ESIs at multiple sites. The most common level for ESI administration was L5 (94 subjects, 77%), followed by L4 (76 subjects, 63%) and S1 (66 subjects, 55%). ESI dose and site and number of injections were similar between male and female patients.
ESI and vBMD
In both groups, vBMD varied by vertebral level, with the lowest vBMD observed at L3. There was no difference in vBMD or relationship between vBMD and ESI between male and female patients. ESI-treated subjects had lower vBMD compared with controls at each vertebral site. Comparison of the mean vBMD at each vertebral level from T12 to L5 is depicted in Fig. 1 .
Compared with controls, ESI subjects had significantly lower vBMD at T12 (-23%, P = 0.002), L1 (-23%, P = 0.003), L3 (-23%, P = 0.04), L4 (-21%, P = 0.03), and L5 (-24%, P = 0.007). At L2, vBMD was lower in ESI subjects, but the difference was not statistically significant (-19%, P = 0.16). We further compared average vBMD at T12 to L5 and found that ESI subjects had significantly lower average vBMD (-19.9%, P = 0.03). Similarly, average vBMD at L1-L2 in the ESI group was significantly lower than control (-20.0%, P = 0.03).
The relationship between cumulative ESI dose and vBMD was also investigated. Greater cumulative dosage was associated with lower average vBMD from T12 to L5 (r = -0.18, P = 0.05; Fig. 2 ). We also specifically evaluated the relationship between cumulative dose and vBMD at L1-L2, the most commonly measured site by CT. A similar small but significant negative correlation was found between cumulative dose and average vBMD at L1-L2 level (r = -0.22, P = 0.02). There was a negative trend between the number of ESI sites and vBMD at L1-L2 level (r = -0.15, P = 0.10).
We further investigated whether patients treated with ESI had lower vBMD at the site of injection compared with more remote vertebrae. This was done by comparing the magnitude of the difference in vBMD between groups at each level, relative to the site of injection, using linear regression. We did not find that the difference in vBMD was greater between patients with ESI and controls at the site of injection compared with other more distal vertebral sites.
Prevalent fractures
CT images were examined for the presence of prevalent vertebral fractures. Vertebral fractures were found in 10 subjects in the ESI group and 11 from the control group. Due to the retrospective study design, we were not able to ascertain whether fractures predated ESI.
Discussion
To our knowledge, this is the first study to use CT to investigate vBMD in patients receiving ESIs. We found that patients treated with ESIs had lower vBMD compared with age-and sex-matched controls. We also demonstrated that larger cumulative dose of ESI was associated with lower vBMD. Our findings extend the few prior DXA-based studies and provide additional evidence that ESIs may negatively impact bone quality. We found that vBMD was lower in patients treated with ESIs compared with controls at each vertebra assessed, from T12 to L5. Prior studies have investigated the association between ESI exposure and aBMD by DXA (30) (31) (32) (33) (34) , with conflicting results. Although some authors have found lower aBMD in patients treated with ESIs (30-32), others have not (33, 34) . Two-dimensional DXA of the spine is prone to artifact in patients receiving epidural steroids for back pain because of pre-existing spinal pathology, which may contribute to discrepant results. Consistent with previous studies, we found that vBMD varied according to vertebral level, with L3 being the lowest in both groups (24) . We observed a difference in spine vBMD of approximately 20% between patients treated with ESIs and controls. This difference is of similar magnitude to the reported difference (22%) between women with low trauma fractures and agematched healthy controls (35) . Although we could not calculate the fracture risk from the current study, our findings are of potential concern, given the prevalence of ESIs, particularly among older patients who have other risk factors for bone loss and fracture.
We found evidence of a dose response relationship between ESI and vBMD. This has been demonstrated for both oral and inhaled glucocorticoids (36) (37) (38) (39) . Using DXA, Kang et al. (30) similarly found evidence of a cumulative effect of ESIs, with a trend toward decreased aBMD at the hip in postmenopausal women who received more than 120 mg of triamcinolone in 1 year. Another cross-sectional study found that postmenopausal women receiving a cumulative dose of triamcinolone of greater than 200 mg had lower BMD at femoral head and total hip compared with controls who had not received any ESIs (31) . A small prospective study found that hip aBMD by DXA decreased over 6 months after a single ESI of 80 mg triamcinolone (32) . However, these results may have been biased given the small sample size, 50% dropout rate, and lack of a control group. In contrast, a small cross-sectional study failed to find a relationship between cumulative ESIs and aBMD in patients with chronic low back pain (34) . The discrepancy among these studies may be related to both insensitivity in the ability of DXA to capture the skeletal impact of ESI and the different steroid doses used in the various populations. The majority of studies that found a negative impact of ESIs included populations using higher ESI doses (30, 31) . Similarly, our study included patients with relatively higher ESI doses, with a median dosage of 340 mg triamcinolone equivalent. As DXA results were available on very few patients in our study, we were not able to perform comparison between DXA and cQCT.
We investigated whether vBMD was lower at the site of injection compared with more remote vertebral sites. Although the majority of patients had received injections at L5, we did not find that the difference in vBMD between groups was larger at L5 compared with other vertebral levels. Our results suggest that ESIs may impact bone through systemic absorption, rather than a local effect. This is consistent with previous work demonstrating suppression of endogenous cortisol and hyperglycemia after ESI (16) .
Our study has several limitations. This is a retrospective, single-center study. Given the retrospective design, we are unable to infer a causal relationship between ESI and vBMD. Further, we were only able to capture ESIs that were given at our institution. In addition, our institution is a tertiary referral center and may not reflect the general population. Patients in both case and control groups may have had ESIs at an outside hospital; however, this would bias toward finding no difference. We were not able to assess an effect of intraarticular steroid injections, as these were not reliably captured in our records. Due to the retrospective design, we were unable to evaluate physical activity. It is possible that patients with ESIs had more pain, which limited their mobility and predisposed to bone loss. Our methodology for vBMD calculation was based solely on trabecular bone. However, previous studies have demonstrated that trabecular bone is predominantly affected by glucocorticoids (22) . Further, as vertebrae are comprised predominantly of trabecular bone, these measures can be used as a reasonable surrogate for whole-bone vBMD. We did not perform finite element analysis to evaluate bone strength, as our quantitative CT analysis is a phantomless method. In our study, individuals in the ESI group had a lower body mass index compared with control group. Although previous studies have shown that different amounts of adipose can cause artifact in aBMD by DXA, vBMD by cQCT, which directly measures the trabecular bone and can distinguish fat, lean mass, and bone, is less affected by surrounding fat (40) , suggesting that this difference in body mass index did not substantially alter our measurements. In this study, we excluded patients with teriparatide use, as teriparatide has been shown to have the strongest impact on LS (41) . Patients using bisphosphonates, hormone replacement treatment, and raloxifene were included in our study. However, use of these medications was rare and was comparable between ESI and control groups. Due to the retrospective study design, we were not able to include other skeletal risk factors such as calcium intake, menopause history, and clinical fracture history. Although we recorded the presence of fracture on the CT scans, due to our study design, we were unable to capture clinical fracture history or ascertain whether fracture-related pain led to administration of ESIs or whether ESIs predated the fracture. Patients treated with ESI may be at greater risk of vertebral fractures. The relationship between ESI and fracture warrants further investigation.
In conclusion, we found that patients receiving ESIs had lower vBMD compared with age-and sex-matched controls. There was a small but substantial association between higher cumulative ESI dose and lower vBMD. These findings are of potential concern, given the prevalence of ESIs, particularly among older patients who have other risk factors for bone loss and fracture. Further prospective studies are needed to investigate the skeletal consequences of ESIs. If our results are confirmed, they would support developing strategies to prevent bone loss in the growing population receiving ESIs.
